GlassScriptPhysician profile
Yasser Asmar
NPI 1265417679
$6,882.71
in general payments reported to CMS, 2019-2025
32 companies · $821 in 2025
The $821 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,405 · 2020: $339 · 2021: $972 · 2022: $574 · 2023: $964 · 2024: $807 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,656.46 | 2019-2024 | Aveir, Freestyle Libre 2, Gallant |
| Biotronik INC. | $922.83 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $457.07 | 2021-2024 | Optimizer |
| Medtronic Vascular, INC. | $425.96 | 2019 | |
| Boston Scientific Corporation | $333.92 | 2023-2025 | Watchman Flx, Spyglass |
| Medtronic, INC. | $282.35 | 2021 | |
| Novo Nordisk INC | $281.50 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $247.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.27 | 2021-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $232.55 | 2019-2022 | |
| Shionogi INC | $201.20 | 2024 | Fetroja |
| Pfizer INC. | $201.04 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $173.53 | 2023-2024 | Spravato, Xarelto |
| Insmed, INC. | $138.88 | 2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $130.35 | 2025 | Vibativ |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $125.00 | 2025 | Nuzyra |
| Napo Pharmaceuticals INC | $121.42 | 2024 | Mytesi |
| Sunovion Pharmaceuticals INC. | $110.75 | 2019 | |
| Merck Sharp & Dohme LLC | $79.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $66.87 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $51.30 | 2023 | Shingrix |
| Ethicon US, LLC | $46.61 | 2019 | |
| Organogenesis INC. | $40.16 | 2021 | |
| Abbvie INC. | $35.85 | 2021 | |
| Cook Medical LLC | $30.34 | 2025 | Zilver Ptx |
| Ironwood Pharmaceuticals, INC | $27.32 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.01 | 2022 | |
| Exact Sciences Corporation | $23.22 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.05 | 2022 | |
| Allergan, INC. | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Asmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.